Investor Presentation Q1 2023

64 Investor presentation First three months of 2023 Novo NordiskⓇ The phase 3a OASIS trial investigating oral semaglutide 50 mg in obesity initiated in Q3 2021 and expected to complete in H1 2023 Global trial planned was started in H2 2021 Plan to include 660 patients with obesity Oral semaglutide 50 mg R 1:1 Placebo oral 68 weeks 7 weeks follow-up Inclusion criteria • BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or • BMI ≥30 kg/m² Weight-related comorbidities are hypertension, dyslipidaemia, obstructive sleep apnoea and CVD OASIS: Oral Semaglutide treatment effect In people with Obesity; CVD: Cardiovascular disease; BMI: Body Mass Index Objective To investigate superiority of oral semaglutide 50 mg vs. placebo on weight loss in people with overweight or obesity Primary endpoint • Change in body weight from baseline (%) Body weight reduction ≥ 5% OASIS programme scope Total of 1,000 patients across three trials: 1) A global (North America and Europe), 2) Japanese and 3) Chinese trial

View entire presentation